Description

URIFINE-T combines a selective α-1 blocker (Tamsulosin MR) and an anti-inflammatory corticosteroid (Deflazacort) to provide powerful relief in conditions associated with urinary obstruction, inflammation, and painful urination. This dual-action therapy helps improve urine flow, reduce swelling, and relieve discomfort caused by prostate enlargement and urinary tract inflammation.

Benefits

• Improves urinary flow by relaxing prostate and bladder neck muscles.

• Reduces inflammation and swelling in urinary pathways.

• Relieves painful or difficult urination (dysuria).

• Helps manage acute flare-ups of prostate-related discomfort.

• Reduces urinary frequency, urgency, and nighttime urination.

• Provides faster symptom control due to anti-inflammatory action.

Mechanism of Action (MOA)

1. Tamsulosin HCl (MR) – 0.4 mg

• A selective α-1A adrenergic receptor blocker.

• Relaxes smooth muscles of:

  • Prostate

  • Bladder neck

  • Urethra

• Improves urine flow, reduces obstruction, and eases urinary symptoms of BPH (Benign Prostatic Hyperplasia).

2. Deflazacort – 30 mg

• A potent glucocorticoid with anti-inflammatory and immunomodulatory properties.

• Reduces inflammation, tissue swelling, and urethral edema, leading to better urine passage.

• Causes fewer side-effects compared to traditional steroids.

Indications

URIFINE-T is indicated for:

• Acute urinary retention

• Dysuria (painful urination)

• Prostatitis with inflammation

• Benign Prostatic Hyperplasia (BPH) symptoms

• Urethral swelling or obstruction

• Post-operative urinary tract inflammation

• Lower urinary tract symptoms (LUTS) with edema